Technical Data
MDR Protein (PE) (MRP1, Multidrug resistance-associated protein 1, ABCC1, ATP-binding cassette sub-family C member 1, Leukotriene C(4) transporter)
MRP1 is a 190kD transmembrane phosphoglycoprotein overexpressed in various human multidrug resistant tumor cell lines and tumors (1-5).

Suitable for use in Western Blot, Immunoprecipitation, Flow Cytometry, Immunocytochemistry and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:100-1:500 (Anti mouse IgG labeled with HRP).
Immunocytochemistry: 1:20-1:50. [PBS, 0.5% paraformaldehyde-fixed or 70% methanol-fixed cytospin preparations (2)].
Immunohistochemistry: FFPE sections following antigen retrieval by microwave heating in citrate (5).
Flow Cytometry: 1:20. Cells fixed in PBS, 0.5% paraformaldehyde for 30 minutes, followed by anti-mouse IgG labeled with FITC. Note: Block and wash with solution containing 0.1% Tween.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C before opening. DO NOT FREEZE! Stable at 4C as an undiluted liquid. Dilute only prior to immediate use. Freezing R-Phycoerythrin (PE) conjugates will result in a substantial loss of activity. Protect from light.
MabIgG13H406Affinity Purified
100ul4C Do not freezeBlue IceHumanMouse
Not determined
Non-denatured membranes prepared from the human small cell lung cancer cell line, H69AR, which highly overexpresses MRP1(1-3).
Purified by affinity chromatography.
Supplied as a liquid in PBS, pH 7.2. Labeled with R-Phycoerythrin (PE).
Recognizes human MDR protein with a defined linear epitope (aa918-924) of MRP1. Does not crossreact with human MDR1, MDR3, MRP2, MRP3, MRP4, MRP5 or MRP6 gene products. Does not crossreact with mouse mrp1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1) Cole, S.P.C. et al. (1992). Science 258: 1650-1654. 2) Hipfner, D.R. et al. (1999). Biochim. Biophys. Acta 1461: 359-376. 3) Hipfner, D.R. et al. (1994). Cancer Res. 54: 5788-5792. 4) Hipfner, D.R. et al. (1996). Cancer Res. 56: 3307-3314. 5) Wright, S. et al. (1998). Clin. Cancer Res. 4: 2279-2289.